These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 29663815

  • 1. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
    Jesenak M, Hrubiskova K, Kapustova L, Kostkova M, Banovcin P.
    Bratisl Lek Listy; 2018; 119(4):198-200. PubMed ID: 29663815
    [Abstract] [Full Text] [Related]

  • 2. Longterm Beneficial Effect of Canakinumab in Colchicine-resistant Familial Mediterranean Fever.
    Laskari K, Boura P, Dalekos GN, Garyfallos A, Karokis D, Pikazis D, Settas L, Skarantavos G, Tsitsami E, Sfikakis PP.
    J Rheumatol; 2017 Jan; 44(1):102-109. PubMed ID: 28042127
    [Abstract] [Full Text] [Related]

  • 3. Effect of anti-interleukin-1 treatment on quality of life in children with colchicine-resistant familial Mediterranean fever: A single-center experience.
    Kurt T, Aydın F, Nilüfer Tekgöz P, Sezer M, Uncu N, Çelikel Acar B.
    Int J Rheum Dis; 2020 Jul; 23(7):977-981. PubMed ID: 32558310
    [Abstract] [Full Text] [Related]

  • 4. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
    Gül A.
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
    [Abstract] [Full Text] [Related]

  • 5. The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.
    Hentgen V, Vinit C, Fayand A, Georgin-Lavialle S.
    Front Immunol; 2020 Apr; 11():971. PubMed ID: 32670263
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
    De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, Koné-Paut I, Lachmann HJ, Ozen S, Simon A, Zeft A, Calvo Penades I, Moutschen M, Quartier P, Kasapcopur O, Shcherbina A, Hofer M, Hashkes PJ, Van der Hilst J, Hara R, Bujan-Rivas S, Constantin T, Gul A, Livneh A, Brogan P, Cattalini M, Obici L, Lheritier K, Speziale A, Junge G.
    N Engl J Med; 2018 May 17; 378(20):1908-1919. PubMed ID: 29768139
    [Abstract] [Full Text] [Related]

  • 9. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
    Kucuksahin O, Yildizgoren MT, Ilgen U, Ates A, Kinikli G, Turgay M, Erten S.
    Mod Rheumatol; 2017 Mar 17; 27(2):350-355. PubMed ID: 27328763
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of Canakinumab in Colchicine- and Anakinra-Resistant or -Intolerant Adult Familial Mediterranean Fever Patients: A Single-Center Real-Life Study.
    Babaoglu H, Varan O, Kucuk H, Atas N, Satis H, Salman R, Ozturk MA, Goker B, Tufan A, Haznedaroglu S.
    J Clin Rheumatol; 2020 Jan 17; 26(1):7-13. PubMed ID: 30048391
    [Abstract] [Full Text] [Related]

  • 11. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A, Derin ME, Albayrak F, Karakaş B, Karagöz Y.
    Adv Rheumatol; 2020 Jan 30; 60(1):12. PubMed ID: 32000860
    [Abstract] [Full Text] [Related]

  • 12. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
    Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F.
    Clin Rheumatol; 2016 Feb 30; 35(2):441-6. PubMed ID: 25213327
    [Abstract] [Full Text] [Related]

  • 13. The clinical role of anakinra in the armamentarium against familial Mediterranean fever.
    Parlar K, Ates MB, Egeli BH, Ugurlu S.
    Expert Rev Clin Immunol; 2024 May 30; 20(5):441-453. PubMed ID: 38133629
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
    Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I.
    Semin Arthritis Rheum; 2011 Oct 30; 41(2):265-71. PubMed ID: 21277619
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö, Kucuk H, Babaoglu H, Guven SC, Ozturk MA, Haznedaroglu S, Goker B, Tufan A.
    Mod Rheumatol; 2019 Mar 30; 29(2):363-366. PubMed ID: 29578360
    [Abstract] [Full Text] [Related]

  • 16. Familial Mediterranean fever, review of the literature.
    Alghamdi M.
    Clin Rheumatol; 2017 Aug 30; 36(8):1707-1713. PubMed ID: 28624931
    [Abstract] [Full Text] [Related]

  • 17. Down-regulated Th17 cells in a patient with familial Mediterranean fever associated with amyloid A amyloidosis in the treatment of canakinumab.
    Goto T, Miyazaki Y, Nakayamada S, Shiraishi N, Yoshinaga T, Tanaka Y, Nakamura T.
    Mod Rheumatol Case Rep; 2023 Jan 03; 7(1):237-242. PubMed ID: 35349715
    [Abstract] [Full Text] [Related]

  • 18. Canakinumab is effective in patients with familial Mediterranean fever resistant and intolerant to the colchicine and/or anakinra treatment.
    Karabulut Y, Gezer HH, Duruöz MT.
    Rheumatol Int; 2022 Jan 03; 42(1):81-86. PubMed ID: 34550430
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.